Chitoshi Goto
Overview
Explore the profile of Chitoshi Goto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Katsuno H, Tachi T, Matsuyama T, Sugioka M, Aoyama S, Osawa T, et al.
Front Pharmacol
. 2021 Dec;
12:761607.
PMID: 34867381
In Japan, medical costs are increasing annually, and the increase in national medical costs, particularly in the direct cost of managing adverse drug events, is high. An in-depth understanding of...
2.
Tachi T, Otsubo M, Toyoshima M, Katsuno H, Ueno A, Noguchi Y, et al.
Int J Health Plann Manage
. 2021 Apr;
36(4):1326-1337.
PMID: 33893659
It is important to clarify the influence of activities of daily living (ADL) at discharge on the discharge destination of hospitalised patients. The Functional Independence Measure (FIM) is a widely...
3.
Sugioka M, Tachi T, Mizui T, Koyama A, Murayama A, Katsuno H, et al.
Sci Rep
. 2020 Dec;
10(1):21341.
PMID: 33288793
In pediatric individuals, polypharmacy would increase the prevalence of adverse drug reactions (ADRs). However, there is no report on the ADR increase adjusted for the influence of concomitant disease types....
4.
Hori A, Sahashi H, Sano S, Matsumiya E, Ariga M, Asano A, et al.
Anticancer Res
. 2020 Dec;
40(12):7101-7108.
PMID: 33288609
Background/aim: It has been reported that some adverse events (AEs) of enzalutamide (ENZ) occur more frequently in Japanese patients with castration-resistant prostate cancer (CRPC) due to higher steady-state trough plasma...
5.
Inoue S, Osawa T, Umeda M, Yasuda M, Mizui T, Sugiyama Y, et al.
Gan To Kagaku Ryoho
. 2020 Aug;
47(8):1189-1192.
PMID: 32829352
Skin complication caused by anti-programmed cell death-1(PD1)antibody is a typical immune-related adverse event. We designed this study to clarify the correlation between risk factors(patient's background and laboratory data)and skin toxicity(...
6.
Tachi T, Otsubo M, Toyoshima M, Murayama A, Katsuno H, Ueno A, et al.
Aging Clin Exp Res
. 2020 May;
33(4):983-990.
PMID: 32458358
Background: The Functional Independence Measure (FIM) evaluates the activities of daily living (ADL), and FIM efficiency represents daily improvement in FIM. Polypharmacy affects both ADL and FIM; however, few studies...
7.
Yasuda M, Osawa T, Nagaya K, Watanabe H, Makino T, Setta E, et al.
Gan To Kagaku Ryoho
. 2019 Oct;
46(10):1547-1551.
PMID: 31631137
Using electronic medical charts at the department of pharmacy of Gifu Municipal Hospital, we constructed a new support system for the prescription inspection of anticancer drug injection preparation via quality...
8.
Tachi T, Kanematsu Y, Aoyama S, Katsuno H, Otsubo M, Ueno A, et al.
Biol Pharm Bull
. 2019 May;
42(5):712-720.
PMID: 31061313
We conducted a retrospective study to investigate adverse drug reactions and associated medical costs among elderly individuals that could be avoided if pharmacotherapy was performed in accordance with the Beers...
9.
Osawa T, Inoue S, Umeda M, Hasegawa T, Makino T, Hori A, et al.
Gan To Kagaku Ryoho
. 2018 Nov;
45(10):1533-1535.
PMID: 30382069
Skin reactions to nivolumab are typical immune-related adverse events. We investigated the relation between patient background and test values before nivolumab administration and skin reactions. From February 2016 to February...
10.
Tanaka K, Hori A, Tachi T, Osawa T, Nagaya K, Makino T, et al.
J Pharm Health Care Sci
. 2018 May;
4:9.
PMID: 29736254
Background: In recent years, cancer chemotherapy is being conducted at outpatient clinics, wherein pharmacists are involved with patient guidance and management of adverse events as experts in medication therapy. Therefore,...